HEMEMICS Biotechnologies, Inc. Receives HHS Support to Develop Rapid Antigen, Antibody Diagnostic to Identify COVID-19 Infected Americans

Rapid Testing and Cloud-based Networking Allow Real-Time Outbreak Alerts for Health Agencies

Read More


Hememics Biotechnologies Received $2.5 Million Investment from AMVI Partners

Vietnamese Investors Back Novel Point-of-Care Technology for Rapid Detection of Pathogens

Read More

HEMEMICS' technology can rapidly transform the $6B blood culture and $20B immunoassay testing markets.


To find out more about how the HEMEMICS technology can uniquely address COVID-19 and other diagnostic challenges, contact us.


HEMEMICS Biotechnologies, Inc.
401 Professional Drive, Suite 220
Gaithersburg, MD 20879-3445

Copyright © HEMEMICS Biotechnologies, Inc.